| Hepcidin, an emerging and important player in brain iron homeostasis D Vela Journal of translational medicine 16 (1), 1-18, 2018 | 100 | 2018 |
| Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications D Vela, Z Vela-Gaxha Experimental & molecular medicine 50 (2), e436-e436, 2018 | 69 | 2018 |
| Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker D Vela Molecular Medicine 24 (1), 1-18, 2018 | 59 | 2018 |
| The dual role of hepcidin in brain iron load and inflammation D Vela Frontiers in Neuroscience, 2018 | 59 | 2018 |
| Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology D Vela Laboratory Investigation 98 (3), 315-326, 2018 | 42 | 2018 |
| Iron metabolism in prostate cancer; from basic science to new therapeutic strategies D Vela Frontiers in oncology 8, 547, 2018 | 36 | 2018 |
| Keeping heart homeostasis in check through the balance of iron metabolism D Vela Acta Physiologica 228 (1), e13324, 2020 | 33 | 2020 |
| Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials D Vela, Z Vela‐Gaxha, M Rexhepi, R Olloni, V Hyseni, R Nallbani British Journal of Clinical Pharmacology, 2021 | 24 | 2021 |
| Low Hepcidin in Type 2 Diabetes Mellitus: Examining the Molecular Links and Their Clinical Implications D Vela, RB Sopi, M Mladenov Canadian journal of diabetes 42 (2), 179-187, 2018 | 18 | 2018 |
| Iron in the Tumor Microenvironment D Vela Tumor Microenvironment, 39-51, 2020 | 16 | 2020 |
| Left ventricular markers of global dyssynchrony predict limited exercise capacity in heart failure, but not in patients with preserved ejection fraction G Bajraktari, A Batalli, A Poniku, A Ahmeti, R Olloni, V Hyseni, Z Vela, ... Cardiovascular ultrasound 10 (1), 1-8, 2012 | 16 | 2012 |
| Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and … D Vela, J Leshoski, Z Vela, M Jakupaj, M Mladenov, RB Sopi BMC Endocrine disorders 17 (1), 1-9, 2017 | 10 | 2017 |
| The Role of Insulin Therapy in Correcting Hepcidin Levels in Patients with Type 2 Diabetes Mellitus D Vela, J Leshoski, ES Gjorgievska, N Hadzi-Petrushev, M Jakupaj, ... Oman medical journal 32 (3), 195, 2017 | 10 | 2017 |
| Systemic and local hepcidin as emerging and important peptides in renal homeostasis and pathology D Vela BioFactors 45 (2), 118-134, 2019 | 5 | 2019 |
| HbA1C, finding the right target in 2018. D Vela Diabetes & metabolic syndrome 12 (4), 607-608, 2018 | 1 | 2018 |
| EP1 Receptor Agonists Augment Hyperoxia-Induced Airway Hyperresponsiveness RB Sopi, B Neziri, M Mladenov, D Vela, N Lajçi, Q Thaqi, K Bislimi, ... The FASEB Journal 30 (1 Supplement), 1263.5-1263.5, 2016 | | 2016 |
| Left ventricular markers of global dyssynchrony predict limited exercise G Bajraktari, A Batalli, A Poniku, A Ahmeti, R Olloni, V Hyseni, Z Vela, ... | | |
